Ignacio O. Zabalza
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Journal: Cancer immunology, immunotherapy : CII
Published: February 05, 2024
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Journal: Minerva urology and nephrology
Published: August 02, 2023
Lipid fingerprint-based histology accurately classifies nevus, primary melanoma, and metastatic melanoma samples.
Journal: International journal of cancer
Published: May 25, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Journal: Targeted oncology
Published: May 22, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Journal: Cancer immunology, immunotherapy : CII
Published: May 04, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Journal: Cancer immunology, immunotherapy : CII
Published: March 13, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Journal: European urology oncology
Published: February 17, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Journal: Clinical genitourinary cancer
Published: December 02, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
Journal: Targeted oncology
Published: July 25, 2022
Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival.
Journal: Critical reviews in oncology/hematology
Published: January 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Journal: Clinical genitourinary cancer
Published: January 15, 2022
Last Updated: 09/26/2026